Stockscreener 앱 받기
1.57
1.57%
-0.025
시간 외 거래:
1.59
0.02
+1.27%
전일 마감가:
$1.595
열려 있는:
$1.69
하루 거래량:
13.23M
Relative Volume:
1.46
시가총액:
$429.97M
수익:
$188.87M
순이익/손실:
$-400.38M
주가수익비율:
-1.2362
EPS:
-1.27
순현금흐름:
$-260.90M
1주 성능:
-36.18%
1개월 성능:
-20.71%
6개월 성능:
-22.28%
1년 성능:
-81.31%
1일 변동 폭
$1.57
$1.69
1주일 범위
$1.56
$2.66
52주 변동 폭
$1.16
$10.65
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PACB | 1.57 | 429.97M | 188.87M | -400.38M | -260.90M | -1.27 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
FY2024 EPS Estimates for PACB Lowered by Cantor Fitzgerald - MarketBeat
DNA Sequencing Market to Grow by USD 17.34 Billion (2024-2028), Driven by Rising NGS Adoption, AI-Powered Report Explores Market EvolutionTechnavio - The Malaysian Reserve
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by UBS Group to "Hold" Rating - MarketBeat
Pacific Biosciences CCO departs amid restructuring By Investing.com - Investing.com Australia
Pacific Biosciences CCO departs amid restructuring - Investing.com India
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y - MSN
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition (NASDAQ:PACB) - Seeking Alpha
Pacific Biosciences of California Inc (PACB) Quarterly 10-Q Report - Quartz
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% Following Analyst Upgrade - MarketBeat
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
UBS Downgrades Pacific Biosciences of California (PACB) - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates - MSN
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock By Investing.com - Investing.com Nigeria
Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock - Investing.com
PacBio’s $459 Million Convertible Note Exchange Offering - Global Legal Chronicle
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00 - MarketBeat
Pacific Biosciences of California Target of Unusually High Options Trading (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Rating Lowered to "Neutral" at UBS Group - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Price Target Raised to $2.50 - MarketBeat
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange - Wilson Sonsini
PacBio to Present at 4 Major Healthcare Investor Conferences Through Year-End | PACB Stock News - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Pacific Biosciences: Q3 Earnings Snapshot - CTPost
Pacific Biosciences of California (FRA:P09) 5-Day RSI : 64.86 (As of Nov. 08, 2024) - GuruFocus.com
PacBio stock falls 16% post-market after Q3 revenue miss - MSN
Pacific Biosciences of California, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings: E - GuruFocus.com
PacBio Announces Third Quarter 2024 Financial Results - GlobeNewswire
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 - StockTitan
Strong week for Pacific Biosciences of California (NASDAQ:PACB) shareholders doesn't alleviate pain of three-year loss - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company - Simply Wall St
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop - StockTitan
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Re - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com
Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep – Company AnnouncementFT.com - Financial Times
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):